La gestione delle MPS entra in una nuova era. Tieniti aggiornato.
References: 1. Hopwood JJ et al. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate 2-sulphatase gene. Hum Mutat 1993;2(6):435–442. 2. Wraith JE et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167(3):267–277. 3. Scarpa M et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011;6:72. 4. Baehner F et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28(6):1011–1017. 5. Guffon N et al. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis 2015; 10:43. 6. Chkioua L et al. Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II. Diagn Pathol 2011;6:42.